Dana Adams, PA
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.7% of the total across 555 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by Medtronic at 49.8% of the total. Among medical clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 555 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- AbbVie$1K
- Boston Scientific$635
- Abbott$573
- Collegium Pharmaceutical, Inc.$468
- Pfizer$448
- plus $3K from 29 others
What the payments were for
- Travel & lodging$1,1749%
- Food & beverage$11,51291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 171 | $6,324 |
| AbbVie(2 entities) | 118 | $1,369 |
| Boston Scientific | 20 | $635 |
| Abbott | 37 | $573 |
| Collegium Pharmaceutical, Inc. | 44 | $468 |
| Pfizer | 33 | $448 |
| Merz Pharmaceuticals, LLC | 15 | $380 |
| IBSA Pharma Inc. | 10 | $245 |
| Johnson & Johnson | 9 | $191 |
| Amgen | 10 | $177 |
| Biohaven Pharmaceuticals, Inc. | 9 | $171 |
| Pacira Pharmaceuticals Incorporated | 7 | $167 |
| Si-bone, Inc. | 6 | $153 |
| Vertex | 6 | $148 |
| Relievant Medsystems, Inc. | 7 | $134 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $128 |
| SPR Therapeutics, Inc | 5 | $119 |
| Tersera Therapeutics LLC | 2 | $111 |
| Vertos Medical, Inc. | 2 | $110 |
| Nevro Corp. | 4 | $97 |
| Lundbeck LLC | 4 | $70 |
| Eisai Inc. | 4 | $54 |
| Curonix LLC | 2 | $52 |
| Biodelivery Sciences International, Inc. | 3 | $47 |
| Arbor Pharmaceuticals, Inc. | 3 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| GRT US Holding, Inc. | 2 | $39 |
| Bioventus LLC | 2 | $36 |
| Acacia Pharma Inc | 2 | $29 |
| Merck | 2 | $27 |
| Currax Pharmaceuticals LLC | 2 | $27 |
| Averitas Pharma Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Avanos Medical | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMEDII$1,808
- INTELLIS ADAPTIVESTIM$604
- INCEPTIV$291
- INTELLIS$225
- Intracept$150
- VANTA ADAPTIVESTIM$117
How this compares
$12,686 in reported general payments places this provider in the 95th percentile of 632 medical providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 119 | $100,765 |
| Xtampza ErOxycodone Myristate | 135 | $87,644 |
| UbrelvyUbrogepant | 50 | $81,771 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 2,108 | $67,308 |
| Oxycodone Hcl | 2,248 | $62,445 |
| BelbucaBuprenorphine Hcl | 83 | $62,197 |
| Nurtec OdtRimegepant Sulfate | 30 | $54,974 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 993 | $33,953 |
| MovantikNaloxegol Oxalate | 51 | $22,515 |
| Fentanyl | 185 | $20,117 |
| QuliptaAtogepant | 17 | $18,425 |
| Buprenorphine | 47 | $14,485 |
| Gabapentin | 916 | $14,043 |
| NucyntaTapentadol Hcl | 12 | $12,310 |
| LinzessLinaclotide | 21 | $12,212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta | $468 | $162,151230 claims |
| AbbVieUbrelvy, Qulipta, Linzess | $1,369 | $112,40888 claims |
| PfizerNurtec Odt, Lyrica | $448 | $65,14041 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 632 medical providers in Virginia.
Other medical in Salem
- Laura DavisSalem$8K
- Bryan UrquhartFredericksburg$264K
- Sara VillalonaRichmond$240K
- Sarah SafaLansdowne$171K
- Waseem GarbiaFairfax$114K
- Rana HassanAshburn$54K
- Brian LamFalls Church$42K
- Christine KesslerKing George$20K
- Janlyn AnthonyRichmond$18K
- Cara DepanfilisNorfolk$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.